<DOC>
	<DOCNO>NCT02093754</DOCNO>
	<brief_summary>This study allow ass liver related injury HIV patient .</brief_summary>
	<brief_title>Assessing Severity Metabolic-related Liver Injuries Aging HIV-monoinfected Patients</brief_title>
	<detailed_description>This study cross-sectional , multicentre study include 7 centre 3 European country ( Belgium , France , Germany ) . The maximum duration study patient 4 month , consist : - screen visit , - inclusion visit perform biologic test exams necessary study , within 1 month screen visit , - result delivery visit within 1 month inclusion visit , disclose result previous investigation . Patients one two non invasive marker suggest significant fibrosis ( ≥F2 ) invite liver biopsy within next 2 month . - `` liver biopsy '' visit , within 2 month visit 2 , liver biopsy select consented patient</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . Age ≥40 year 2 . Infection HIV1 3 . Cumulative exposure cART least 5 year currently cART 4 . Viral load &lt; 400 copies/mL 5 . CD4 count &gt; 100 CD4/mm3 6 . Female may eligible enter participate study : nonchildbearing potential define either postmenopausal ( 12 month spontaneous amenorrhea ≥45 year age ) physically incapable become pregnant document tubal ligation , hysterectomy bilateral oophorectomy childbearing potential negative blood pregnancy test screen visit 7 . Informed consent sign prior study procedure 8 . To cover medical insurance ( French centre ) 9 . Presence : metabolic syndrome define recent international consensus definition ( Alberti et al . Circulation 2009 ) include three component among follow criterion : visceral obesity ( waist circumference : Europeans Africans ≥ 94 cm men ≥ 80 cm woman , Americans ≥ 102 cm men ≥ 88 cm woman , Asians ≥ 90 cm men ≥ 80 cm woman ) blood glucose ≥ 1 g/L ( 5,6 mmol/L ) antidiabetic treatment , serum triglyceride ≥ 1,5 g/L ( 1,7 mmol/L ) hypertriglycerides treatment , serum HDL cholesterol &lt; 0,4 g/L ( 1 mmol/L ) men &lt; 0,5 g/L ( 1,3 mmol/L ) woman hypercholesterolemia treatment , blood pressure ( Diastolic ≥130 mmHg and/or Systolic ≥ 85 mmHg ) antihypertensive treatment and/or clinical lipoatrophy and/or lipohypertrophy use clinical questionnaire use validate previous publish study ( ANRS 121 Hippocampe trial ) , and/or chronic elevate transaminase ≥ 1.5 ULN / GGT ≥ 2 ULN confirm two blood sample within least threemonth interval twelve month prior screen visit . 1 . Coinfection hepatitis B ( positive HBs antigen isolate positive HBc antibody positive PCR ) 2 . Positive HCV serology 3 . Coinfection HIV1 HIV2 4 . Use intravenous drug within last six month 5 . Excessive alcohol intake ( male &gt; 50 g/d , female &gt; 40 g/d ) 6 . Other cause liver disease i.e : viral hepatitis , hemochromatosis , Wilson disease , autoimmune hepatitis , primary secondary biliary cirrhosis , primary secondary cholangitis , α1 antitrypsine deficiency 7 . Other cause liver steatosis : current steroid therapy , current therapy amiodarone , tamoxifen , methotrexate , nifedipine , hycanthone ; history cancer chemotherapy ; short bowel syndrome , polycystic ovarian syndrome , WeberChristian disease 8 . Active opportunistic infection except candida oesophagitis 9 . Current Cancer 10 . Pregnancy 11 . Decompensated heart failure 12 . Subject legal guardianship 13 . Inability give inform consent incapacitation 14 . Contraindication MRI : pacemaker , neurovascular surgery , intraocular material , cochlear implant , severe claustrophobia 15 . Participation another study ongoing exclusion period screen</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>